India eyes 40–45% local value addition in next medical-device PLI
The Department of Pharmaceuticals is weighing a new medical-device PLI focused on component makers, with early beneficiaries expected to reach 40–45% domestic value addition. CDSCO is also expanding audit capacity as device regulation and approvals scale.
What happened
Department of Pharmaceuticals · India is considering a next medical-device PLI that favours component makers and pushes early beneficiaries toward 40-45% local
Key facts
- 40-45% targeted domestic value addition
- 43% growth in domestic medical-device manufacturing over four years
- 117 investigational devices
- Up to 30,000 product approvals/licences
- 4,108 licensed medical-device manufacturers
- 20 new medical-device officers
- FY21 first-round PLI applications
Why this matters
Strategic buyers should assess partnerships or acquisitions among Indian device-component makers, where policy incentives and expanding regulatory oversight may accelerate scale and market consolidation.
What to watch
- Formal PLI scheme launch, eligible product/component list, incentive rates, minimum investment thresholds, and domestic-value-addition calculation rules.
- Department of Pharmaceuticals guidance on whether incentives prioritize components, subassemblies, diagnostics, consumables, or finished devices.
- CDSCO hiring, audit frequency, inspection findings, approval turnaround times, and enforcement actions against unregistered or noncompliant products.
- Announcements of Indian investments in device components, cleanrooms, testing laboratories, sterilization capacity, and precision manufacturing.
- Changes in import duties, quality-control orders, public-procurement preferences, or hospital tender localization requirements.
- Evidence that domestic-value-addition targets reach 40–45% without deterioration in device reliability, clinical performance, or warranty claims.
- Map medical-device SKUs and private-label opportunities by imported-component exposure, especially consumables, diagnostics, monitoring, and home-care devices.
- Qualify domestic component and finished-device suppliers with CDSCO documentation, audit readiness, traceability, and post-market surveillance capabilities.
- Build dual-sourcing plans during the transition, since audit-related approval delays or supplier exits could temporarily disrupt availability.
- Review procurement contracts for localization-linked pricing, quality warranties, recall liability, and continuity-of-supply clauses.
- Track whether domestic suppliers can convert PLI support into lower landed costs rather than merely offsetting compliance and capex expenses.